Navigation Links
NxStage® Reports Fourth Quarter and Full-Year 2010 Financial Results; Revenue Growth Exceeds Company Guidance
Date:2/17/2011

LAWRENCE, Mass., Feb. 17, 2011 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported financial results for the three and twelve months ended December 31, 2010, that includes revenue above the top end of its guidance range.

Net revenue for the twelve months ended December 31, 2010 increased 21 percent to $179.2 million compared with revenue of $148.7 million for the full-year 2009.  Revenue for the fourth quarter of 2010 increased 23 percent to a record $49.8 million compared with revenue of $40.5 million for the fourth quarter of 2009.  The increase in both periods was driven by the Company's solid performance in Home and Critical Care, which experienced annual growth of 35 percent and 26 percent, respectively, over 2009.  

Home revenue grew to $85.8 million for the full-year 2010 compared with revenue of $63.5 million for the full-year 2009.  Home revenue increased to $23.6 million in the fourth quarter of 2010 compared with revenue of $17.5 million in the fourth quarter of 2009, representing a 34 percent increase.

Critical Care revenue grew to $28.1 million for the full-year 2010 compared with revenue of $22.3 million for the full-year 2009.  Revenue in Critical Care increased to $8.6 million in the fourth quarter of 2010, compared with revenue of $7.0 million in the fourth quarter of 2009, representing a 23 percent increase.

Annual revenue from the Company's Medisystems in-center business was $65.4 million for the full-year 2010, compared with revenue of $62.9 million for the full-year 2009.  Fourth quarter revenue was $17.6 million, compared with $16.0 million in the fourth quarter of 2009.

"2010 was a year of solid revenue growth for NxStage.  Our strong fourth quarter results capped a year in which we successfully executed against our strategic initiatives, made significant progress in the Home, and gained momentum across all three markets," stated Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical, Inc.  

Burbank continued, "We are on a multi-year growth agenda, and I believe that our strategy is right on course.  Entering 2011, we have good underlying market fundamentals, a strong balance sheet, a solid operating model, as well as a culture of innovation. We remain confident in our ability to build on our momentum moving forward."

NxStage reported a net loss of $31.7 million or ($0.66) per share for the full-year 2010 compared with a net loss of $43.5 million or ($0.93) per share for the full-year 2009.  The Company reported a net loss of $6.3 million or ($0.13) per share for the fourth quarter of 2010 compared with a net loss of $8.7 million or ($0.19) per share for the fourth quarter of 2009.

For the full-year 2010, the Company reported Adjusted EBITDA, adjusted for stock-based compensation, deferred revenue recognized and other non-cash expenses, of $0.5 million, compared with an Adjusted EBITDA loss of $12.7 million for the full-year 2009.  For the fourth quarter of 2010, Adjusted EBITDA was $1.5 million compared with an Adjusted EBITDA loss of $1.2 million in the fourth quarter of 2009.  (See the exhibits for a reconciliation of this non-GAAP measure.)

Effective January 1, 2011, NxStage adopted Accounting Standards Update (ASU) 2009-13 and ASU 2009-14.  Under the new accounting standards, beginning January 1, 2011 revenue from international equipment sales will be recognized upon delivery to distributors rather than ratably over a period of five years.  The new accounting standards have been adopted prospectively and therefore, revenue from equipment shipped prior to January 1, 2011 will continue to be recognized ratably.

Guidance:

For the first quarter of 2011, the Company is forecasting revenue to be between $48.0 million and $49.5 million, a net loss in the range of $5.5 to $6.5 million or ($0.10) to ($0.12) per share, and Adjusted EBITDA in the range of $0.5 to $1.5 million.  

For the full fiscal year 2011, the Company is forecasting revenue to be between $205 million and $213 million, a net loss in the range of $19 to $23 million or ($0.36) to ($0.43) per share, and Adjusted EBITDA  in the range of $6 million to $10 million.  The Company expects to achieve consolidated gross margins of between 38 percent to 42 percent in the fourth quarter of 2011.  

This release contains a non-GAAP financial measure; a reconciliation of the Company's non-GAAP financial measure to its most comparable GAAP financial measure is in the exhibits to this press release.

Conference Call:NxStage will also host a conference call at 9:00 a.m. Eastern Time on Thursday, February 17, 2011 to discuss its fourth quarter and year-end 2010 financial results. To listen to the conference call, please dial 866-804-6927 (domestic) or 857-350-1673 (international).  The passcode is 25783380.   The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at www.nxstage.com/ir.cfm.

A replay of the conference call will be available 2 hours after the start of the call through February 24, 2011.  To access the replay dial 888-286-8010 (domestic) or 617-801-6888 (international) and enter passcode 70668341.  An online archive of the conference call can be accessed via the investor relations section of the Company's website at www.nxstage.com/ir.cfm.

About NxStageNxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenue, loss, gross margin and Adjusted EBITDA numbers, expectations with respect to market momentum of further product innovation, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our major customers, including DaVita Inc., and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the period ended September 30, 2010.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.Contact:Kristen K. Sheppard, Esq.VP, Investor Relationsksheppard@nxstage.comNon-GAAP Financial Measure

The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States and may be different from similar non-GAAP financial measures used by other companies. The non-GAAP financial measure disclosed by the Company is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. Management uses Adjusted EBITDA (EBITDA adjusted for stock based-compensation, deferred revenue recognized, and other non-cash expenses) to understand cash generated from or used in operations.  The Company believes the non-GAAP financial measure provides useful and supplementary information allowing investors greater transparency to one measure used by management.  The non-GAAP financial measure is meant to supplement, and to be viewed in conjunction with, GAAP financial measures.  The non-GAAP financial measure is reconciled to the most comparable GAAP financial measure below.

NxStage Medical, Inc.Consolidated Statements of Operations(in thousands, except per share data)(unaudited)Three Months EndedTwelve Months EndedDecember 31,December 31,2010200920102009Revenues

$49,769$40,510$179,218$148,676Cost of revenues

32,17729,063121,091111,812Gross profit

17,59211,44758,12736,864Operating expenses:Selling and marketing

9,1327,95634,16630,047Research and development

3,5312,43412,9009,814Distribution

3,9203,44214,75113,918General and administrative

6,1705,02022,77419,532Total operating expenses

22,75318,85284,59173,311Loss from operations

(5,161)(7,405)(26,464)(36,447)Other expense:Interest income

33335Interest expense

(1,165)(1,020)(4,597)(6,522)Other income (expense), net

242(288)114(268)(920)(1,305)(4,480)(6,755)Net loss before income taxes

(6,081)(8,710)(30,944)(43,202)Provision for income taxes

212(33)768265Net loss

$ (6,293)$ (8,677)$ (31,712)$ (43,467)Net loss per share, basic and diluted

$   (0.13)$   (0.19)$
(0.66)$
(0.93)Weighted-average shares outstanding, basic and diluted

50,23346,70448,18846,627NxStage Medical, Inc.Consolidated Balance Sheets(amount in thousands, except share data)(unaudited)December 31,December 31,20102009ASSETSCurrent assets:Cash and cash equivalents

$
4,339$
21,720Accounts receivable, net

14,10714,238Inventory

34,95028,117Prepaid expenses and other current assets

2,0841,227Total current assets

155,48065,302Property and equipment, net

8,29010,336Field equipment, net

13,66021,726Deferred cost of revenues

40,08127,799Intangible assets, net

25,41228,208Goodwill

42,69842,698Other assets

473909Total assets

$
286,094$
96,978LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable

$
,811$
9,827Accrued expenses

19,5379,377Current portion of long-term debt

4361Total current liabilities

36,39129,265Deferred revenues

55,36638,490Long-term debt

40,45437,854Other long-term liabilities

1,7541,923Total liabilities

133,965107,532Commitments and contingenciesStockholders’ equity:Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of December 31, 2010 and 2009

--Common stock: par value $0.001, 100,000,000 shares authorized; 54,043,317 shares issued as of December 31, 2010 and 46,795,859 shares issued and outstanding as of December 31, 2009

5347Additional paid-in capital

465,642365,548Accumulated deficit

(308,426)(276,714)Accumulated other comprehensive income

85565Treasury stock, at cost: 325,104 shares as of December 31, 2010

(5,225)-Total stockholders’ equity

152,12989,446Total liabilities and stockholders’ equity

$
286,094$
96,978NxStage Medical, Inc.Cash Flows from Operating Activities(amounts in thousands)(unaudited)Twelve Months EndedDecember 31,20102009Cash flows from operating activities:Net loss

$
(31,712)$
(43,467)Adjustments to reconcile net loss to netcash provided by (used in) operating activities:Depreciation and amortization

22,37920,778Stock-based compensation

15,3519,226Other

2,3192,690Changes in operating assets and liabilities:Accounts receivable

235(2,208)Inventory

(28,744)(9,209)Prepaid expenses and other assets

(877)1,513Accounts payable

(2,781)2,568Accrued expenses and other liabilities

10,065(119)Deferred revenues

16,8765,071Net cash provided by (used in) operating activities

$
3,111$
(13,157)NxStage Medical, Inc.Revenues by Segment(amounts in thousands)Three Months EndedTwelve Months EndedDecember 31,December 31,2010200920102009System One segment  Home

$ 23,558$ 17,547$   85,762$   63,461  Critical Care

8,5656,95928,09322,340Total System One segment

32,12324,506113,85585,801In-Center segment

17,64616,00465,36362,875Total

$ 49,769$ 40,510$ 179,218$ 148,676NxStage Medical, Inc.Non-GAAP Financial Measures(amounts in millions)(unaudited)Three Months EndedTwelve Months EndedDecember 31,December 31,2010200920102009Net loss

$ (6.3)$ (8.7)$ (31.7)$ (43.5)Less: Depreciation, amortization, interest, and taxes

6.76.727.727.9Less: Adjusting items*

1.10.84.52.9Adjusted EBITDA gain (loss)

$  1.5$ (1.2)$
.5$ (12.7)* Adjusting items include stock-based compensation, deferred revenue recognized and other non-cash expensesNxStage Medical, Inc.Non-GAAP Financial Guidance(amounts in millions)Three Months EndedTwelve Months EndedMarch 31, 2011December 31, 2011High

EstimateLow
EstimateHigh
EstimateLow
EstimateNet loss

$
(5.5)$
(6.5)$
(19.0)$
(23.0)Less: Depreciation, amortization, interest, and taxes

7.37.330.230.2Less: Adjusting items*

(0.3)(0.3)(1.2)(1.2)Adjusted EBITDA gain

$
.5$
.5$
.0$
.0* Adjusting items include stock-based compensation, deferred revenue recognized and other non-cash expenses
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage® to Report Fourth Quarter and Full Year 2010 Financial Results
2. NxStage® Appoints Nancy J. Ham to Its Board of Directors and Announces Resignation of Board Member Jonathan T. Silverstein
3. First NxStage® Home Hemodialysis Patients Celebrate Seven-Year Anniversary
4. NxStage® Expands Product Portfolio With Innovative Patient Access Surveillance Solution From Vasc-Alert™
5. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
6. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
7. Masimo Reports Fourth Quarter and Full Year 2010 Financial Results; Provides 2011 Guidance
8. Allscripts Reports Fourth Quarter Results
9. Mesa Labs Reports 44% Increase in Third Quarter Revenues
10. ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China
11. Cambrex Reports Fourth Quarter and Full Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... --  Intarcia Therapeutics, Inc. today announced the appointment ... newly created role of Vice President, Head of Global ... decades of leadership experience at leading pharmaceutical, biotechnology, and ... center. Most recently Dr. Yee served as VP, Head ... Medical Officer at AstraZeneca, where he led medical affairs ...
(Date:2/8/2016)... 8, 2016 /PRNewswire/--  Cell Applications, Inc. and ... services are now available in North ... (3D) bioprinting approach called the "Kenzan Method." Utilizing ... a state-of-the-art robotic system that fabricates 3D tissue ... pay-for-service bio-printing model that makes scaffold-free tissue available ...
(Date:2/8/2016)... -- Velano Vascular, a medical technology company transforming and ... practitioners, announced today that the company has raised an ... proceeds from this financing, an extension of a $5 ... support the development and commercialization of the company,s inpatient ... Philadelphia , and a number of ...
Breaking Medicine Technology:
(Date:2/8/2016)... Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired ... also was the American Cancer Society’s 2015 CEO of the Year , helped ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... of organizations. DocuSyst provides a cloud hosted environment for FileHold software that ... integration with various 3rd party applications using the FileHold web services API. DocuSyst ...
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their ... removal products. , Moles are derived from a cluster of melanin when exposed to ... wrong places and create a lifetime of embarrassment. Historically, mole removal has ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to ... the U.S. require dental technicians to be certified or obtain continuing education. To ... created the “What’s In Your Mouth?” campaign to inform dentists and patients about ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... has added Kybella® to his medical and surgical expertise. Technically known as deoxycholic ... injectable medication used as a non-surgical alternative for reduction of fat below the ...
Breaking Medicine News(10 mins):